Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02340520 · ClinicalTrials.gov registry record · Phase 3
Enhancement of Corticosteroid Efficacy in COPD
A Phase 3 study, sponsored by UConn Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT02340520: Completed Phase 3 study, sponsored by UConn Health.
NCT02340520 is a Phase 3 study that has completed, run by UConn Health. The registered enrollment target is 13 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02340520, a Phase 3 study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a pilot study designed to evaluate the effects of theophylline and roflumilast on circulating Histone deacetylase (HDAC) levels in subjects with COPD, and the bronchodilator effects of corticosteroids. Studies will be performed in 10 subjects with COPD nonresponsive to bronchodilators. Subjects will receive theophylline tablets for 1 week, followed by measurement of circulating HDAC and the acute effect of oral prednisone on the bronchodilator response to inhaled beta agonist. Roflumilast tablets will be added to the theophylline for a further week and the studies repeated. The study will provide preliminary data on the effects of theophylline and roflumilast on circulating HDAC levels and the effects of corticosteroids on the beta agonist bronchodilator response in COPD.
Primary Outcome
Change in FEV1 L and FVC L
Interventions
- DRUG Theophylline
- DRUG Roflumilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
What the finished NCT02340520 record still lists
NCT02340520 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Theophylline is the first listed.
NCT02340520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02340520 about?
NCT02340520 is a clinical study titled "Enhancement of Corticosteroid Efficacy in COPD". This is a pilot study designed to evaluate the effects of theophylline and roflumilast on circulating Histone deacetylase (HDAC) levels in subjects with COPD, and the bronchodilator effects of corticosteroids. Studies will be performed in 10 subjects with COPD nonresponsive to bronchodilators. Subje...
What is the current status of trial NCT02340520?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2014-12. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02340520?
The interventions under investigation include: Theophylline (DRUG), Roflumilast (DRUG).
Who is sponsoring clinical trial NCT02340520?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02340520's enrollment target sits among peer trials
13 1984th of 2000 higher than 17 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia